1. Scrip
  2. >>Archive

Queen's awards for UK industry and MHRA executives

 
• By John Davis

The Queen's birthday honours list, published earlier this month, included CBEs for Dr June Raine, the director of vigilance and risk management at the Medicines and Healthcare products Regulatory Agency (MHRA), and Dr Malcolm Skingle, director of academic liaison at GlaxoSmithKline's worldwide business development team. Pfizer's Dr Annette Doherty, senior vice-president, worldwide pharmaceutical sciences, was awarded an OBE, as was Dr Linda Magee, for services to the biotechnology industry.

The Queen's birthday honours list, published earlier this month, included CBEs for Dr June Raine, the director of vigilance and risk management at the Medicines and Healthcare products Regulatory Agency (MHRA), and Dr Malcolm Skingle, director of academic liaison at GlaxoSmithKline's worldwide business development team. Pfizer's Dr Annette Doherty, senior vice-president, worldwide pharmaceutical sciences, was awarded an OBE, as was Dr Linda Magee, for services to the biotechnology industry.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 
• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.